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ABSTRACT
Background
Improving access to better, more efficient, and rapid 
cancer diagnosis is a necessary component of a high-
quality cancer system. How diagnostic services 
ought to be organized, structured, and evaluated is 
less understood and studied. Our objective was to 
address this gap.
Methods
As a quality initiative of Cancer Care Ontario’s 
Program in Evidence-Based Care, the Diagnostic As-
sessment Standards Panel, with representation from 
clinical oncology experts, institutional and clinical 
administrative leaders, health service researchers, 
and methodologists, conducted a systematic review 
and a targeted environmental scan of the unpublished 
literature. Standards were developed based on ex-
pert consensus opinion informed by the identified 
evidence. Through external review, clinicians and 
administrators across Ontario were given the oppor-
tunity to provide feedback.
Results
The body of evidence consists of thirty-five published 
studies and fifteen unpublished guidance documents. 
The evidence and consensus opinion consistently 
favoured an organized, centralized system with 
multidisciplinary team membership as the optimal 
approach for the delivery of diagnostic cancer as-
sessment services. Independent external stakehold-
ers agreed (with higher mean values, maximum 5, 
indicating stronger agreement) that dap standards are 
Cancer diagnostic assessment 
programs: standards for the  
organization of care in Ontario
M. Brouwers PhD,*† T.K. Oliver BA,*† J. Crawford MSc,† 
P. Ellison MD,‡ W.K. Evans MD,§ A. Gagliardi PhD,|| 
J. Lacourciere MIM,# D. Lo MD,** V. Mai MD,†† 
S. McNair PhD,*† T. Minuk MD,‡‡ L. Rabeneck MD,†† 
C. Rand MSc MA,§ J. Ross RN BSCN MBA,†† J. Smylie BN,§§ 
J. Srigley MD,‡‡ H. Stern MD,††|||| and M. Trudeau MD††
needed (mean: 4.6), that standards should be formally 
approved (mean: 4.3), and importantly, that standards 
reflect an effective approach that will lead to quality 
improvements in the cancer system (mean: 4.5) and 
in patient care (mean: 4.3).
Interpretation
Based on the best available evidence, standards for the 
organization of daps are offered. There is clear need 
to integrate formal and comprehensive evaluation 
strategies with the implementation of the standards 
to advance this field.
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1.  INTRODUCTION
The provision of efficient and rapid cancer diag-
nosis is a necessary component of a high-quality 
cancer system, but how diagnostic services ought 
to be organized, structured, and evaluated is less 
understood and studied. The inefficient and inappro-
priate use of diagnostic imaging procedures (test 
duplication, inappropriate tests ordered) can have 
substantial resource implications and can delay pa-
tient treatment—a serious health care concern. One 
prospective Canadian study found that median wait 
times to diagnosis were 37 days, 71 days, and 81 days 
for patients with lung, colorectal, and prostate cancer 
respectively 1. In relation to lung cancer, Liberman et 
al. 2 reported mean and median wait times of 208 and 
109 days respectively between initial contact with a 
physician or first onset of symptoms and diagnostic 30
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surgery. Similarly, data from seven Canadian prov-
inces measuring the time from an abnormal breast 
screen to diagnosis showed a median time to diagnosis 
of 3.7 weeks; 10% of women waited 9.6 weeks or 
longer for a diagnosis 3.
Diagnostic assessment programs (daps) are one 
component of an overall rapid-access strategy for 
diagnosis. The daps may be either actual or virtual 
entities characterized by facilitated access to com-
prehensive diagnostic services, multidisciplinary 
consultative expertise, patient information resources, 
and psychosocial supports. Programs of this type have 
been associated with high patient satisfaction 4–7, a 
reduction in time from diagnosis to the initiation of 
treatment for various disease sites 5,8, and potentially, 
improvements in clinical outcomes 9. However, less 
clear are the organizational and practice setting fea-
tures that define a high-quality dap, the role of a dap 
in a comprehensive rapid-access strategy, the defining 
features of a dap that lend themselves to unique geo-
graphic or jurisdictional situations, and the indicators 
that should be used to measure quality and impact.
In the province of Ontario, the population of ap-
proximately 12 million people is spread over more 
than 1 million square kilometres, and the distribution 
of new cancer cases varies considerably across the var-
ious regions serving that population 10. Population size 
and geographic spread are important considerations 
in strategizing about quality improvement actions 
meant to increase access and to reduce wait times to 
diagnosis. At the same time, it must be acknowledged 
that solutions for one region may or may not be gener-
alizable to another. In Ontario, approximately 65,000 
new cases of cancer per year are predicted 11, with 
most patients presenting with lung, breast, colorec-
tal, or prostate cancer 11. These patients will require 
a high standard of care, starting with their entry into 
the cancer system. As opposed to current opportunistic 
systems, an organized entry into the cancer system 
and diagnostic processes has the potential to reduce 
duplication of tests, to improve efficiency, to reduce 
costs and waiting times, to enhance the overall quality 
of care for patients throughout the cancer system, and 
conceivably, to improve the outcome of treatment.
The objectives of the Ontario standards for the 
organization of care for cancer daps are to provide 
advice to administrators, planners, and government 
on the optimal strategic planning and investment 
options required to provide the highest standard of 
care for patients with cancer. The Diagnostic Assess-
ment Standards Panel was convened to work with the 
Program in Evidence-Based Care (pebc) to develop 
recommendations that could guide the design, imple-
mentation, and evaluation of daps in Ontario.
2.  METHODS
The Diagnostic Assessment Standards Panel, com-
posed of clinical oncology experts, regional vice 
presidents, clinical administrative leaders, health 
service researchers, and methodologists (Table i), 
conducted a systematic review and environmental 
scan of the literature to help inform the development 
of provincial standards. External validation of the 
standards was conducted through an external review 
by relevant practitioners and administrators through-
out the province of Ontario.
2.1  Search Strategy
A systematic review published by Gagliardi et al. in 
2004 12 served as the evidence foundation for the 
current standards for practice. In that systematic re-
view, the authors identified twenty relevant studies, 
published up to 2002, that evaluated both the clinical 
and the economic components of daps for suspected 
cases of breast, colorectal, lung, head-and-neck, 
prostate, and other cancers.
The search of the literature was conducted using 
mesh and the keyword terms “ambulatory care facili-
ties/ OR community health centers/ OR outpatient 
clinics, OR hospital/Ambulatory Care/ OR cancer 
care facilities/ OR (keywords: rapid or same day or 
one stop or multidisciplinary AND clinic AND diag-
nosis) AND Breast Neoplasms/di OR Prostatic neo-
plasms/di OR Lung neoplasms/di OR Exp colorectal 
neoplasms/di or Exp head and neck neoplasms/di OR 
prostatic neoplasms OR breast neoplasms OR lung 
neoplasms OR exp colorectal neoplasms OR Exp 
head and neck neoplasms”. The search was limited 
to English-language citations.
The original literature search, which spanned 
1985–2002, was updated to October 2006 using med-
line (ovid: 2002 through October 2006), embase (ovid: 
2002 to October 2006), the Cochrane Library (ovid; 
Issue 3, 2006), the Canadian Medical Association 
Infobase, and the National Guideline Clearinghouse. 
Reference lists of related papers and recent review 
articles were also scanned for additional citations.
2.2  Selection Criteria
Articles were included in the systematic review of 
the evidence they met these criteria:
●    Study design:  Randomized controlled trials (rcts), 
case–control studies, and prospective or retro-
spective cohort studies (letters, editorials, and 
comments were excluded)
●    Publication interval:  January 2002 through Octo-
ber 2006
●    Unit of study:
  ●    Diagnostic assessment programs or units, or one-
stop, fast-track, or rapid-access clinics with
  ●    a focus on care provision for patients with 
suspected cancer, and
  ●    encompassing the diagnostic assessment of 
patients with a potential malignancy.
●    Language:  English31
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Quality of the primary studies was assessed using 
common appraisal tools, including the domains from 
the Jadad scale 13 (for rcts) and Downs and Black 14 
for observational studies.
The environmental scan involved two processes. 
First, inquiries were made directly to key cancer lead-
ers and contacts in Ontario, Canada, and to selected 
groups outside of Canada. Second, a targeted Internet 
search was undertaken of key sites, including profes-
sional associations, guideline registries, and health 
care organizations (Table ii). Any reports detailing 
models, frameworks, descriptions, and evaluations 
of daps (including quality improvement initiatives) 
from these targeted individuals, organizations, or 
information sources were considered eligible for in-
clusion. No specific quality evaluation criteria were 
applied, because no scales or quality domains have 
been evaluated using traditional health measurement 
principles.
3.  RESULTS
The evidence base comprises thirty-four published 
studies 4,7,15–46 and fifteen unpublished guidance 
documents 47–61. The present report focuses on a brief 
overview of the evidence found. The reader is referred 
to the full systematic review and environmental scan 
report (published elsewhere) for a full description and 
report of the evidence 62.
3.1  Systematic Review
3.1.1  Search Results
The original systematic review by Gagliardi et al. 12 
included twenty articles that described outcomes 
related to specific disease-site assessment units: 
eleven for breast cancer 4,15–24, three for colorectal 
cancer 7,25,26, and six for head-and-neck cancer 31–36. 
There were seventeen case series that involved 
38–3119 patients, two rcts that included 478 and 791 
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patients, and one case–control study that included 177 
cases and 162 controls 4,7,15–26,31–36. The update of 
the literature search identified 823 citations in which 
patient outcomes related to diagnostic assessment 
units were described for colorectal cancer in four 
studies 27–30, head-and-neck cancer in two studies 37,38, 
lung cancer in two studies 39,40, gynecologic cancers in 
three studies 41–43, neurologic cancers in one study 44, 
lymph node cancers in one study 45, and upper gas-
trointestinal cancers in one study 46. Study designs 
included one small rct (88 patients), seven prospec-
tive cohort studies (359–3637 patients), and six ret-
rospective studies (69–930 patients) 27–30,37–46.
Elements of the Downs and Black quality assess-
ment scale for observational studies 14 were used to 
assess the quality of relevant studies included in the 
updated review. Four key domains were used in the 
evaluation of comparability of subjects, exposure 
or intervention, outcome measure, and statistical 
analysis. The quality of the studies was variable, but 
generally modest, with approximately half the studies 
not using a comparative control group, thus increasing 
the risk for selection bias.
3.1.2  Outcomes
The overall findings from Gagliardi et al. 12 included 
the benefits of diagnostic assessment services in 
terms of reduced wait times for specific diagnostic 
procedures, increased patient satisfaction, and re-
duced anxiety for patients with negative findings. 
Most patients were diagnosed at the initial visit, 
and most diagnoses were confirmed by a pathology 
determination. A number of studies reported increased 
anxiety in women diagnosed with breast cancer at 
one-stop clinics, and one study measured clinical 
outcomes for breast cancer patients.
For the updated systematic review, all studies 
but one were undertaken in the United Kingdom 
and included the National Health Service referral 
guidelines as a quality performance indicator for 
improving timely access 27–30,37–41,43–46. Only one 
study evaluated the cost of follow-up visits to gen-
eral practitioners in an rct evaluating a centralized 
two-stop rapid assessment unit against conventional 
routine diagnostic evaluation 39. Ten studies defined 
cancer-specific risk criteria for general practitioners 
to utilize in their risk assessment and decision-making 
to expedite high-risk referrals to rapid diagnostic 
units 27,28,30,38,41–46. Numerous studies evaluated or 
addressed a multidisciplinary team approach for the 
rapid diagnostic assessment of cancer 37–40,43,45.
The findings from the update of the literature were 
similar to those reported by Gagliardi et al. 12:
●    Most of the studies evaluating rapid diagnostic 
assessment for suspected cases of cancer demon-
strated a reduced time from first referral to special-
ist visit and time to first treatment in that setting.
●    The studies that evaluated patient satisfaction 
found greater patient satisfaction with service 
provision and personal care given by medical 
staff 30,35,42.
table ii  Environmental scan of the literature
Target Source Method
Local jurisdictions Ontario regions Direct inquiry
British Columbia Direct inquiry
Alberta Direct inquiry
Saskatchewan Direct inquiry
Manitoba Direct inquiry
Quebec Direct inquiry
Nova Scotia Direct inquiry
Newfoundland Direct inquiry
Guideline directories Ontario Guidelines Advisory Committee Internet search
Other American Society of Clinical Oncology Internet search
American College of Radiologists Direct inquiry,
Internet search
Canadian Association of Radiologists Direct inquiry,
Internet search
Canadian Strategy for Cancer Control Direct inquiry,
Internet search
National Health Services, United Kingdom Internet search
Scottish Intercollegiate Guidelines Network, Scotland Internet search
Standards, Options, Recommendations, France Internet search
Veterans Affairs, United States Internet search
New Zealand Internet search
Australia Direct inquiry,
Internet search
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●    Studies assessing multidisciplinary care found 
that it translated into a more comprehensive pa-
tient assessment and might contribute to better 
care overall 35,37,38,40,43,45,.
●    Various studies reported that specific referral 
criteria for individual cancer types aided in 
decision-making for general practitioners and 
might assist in ensuring appropriate referral 
for high-risk suspected cases of cancer to rapid 
daps 27,28,30,38,41–46.
3.2  Environmental Scan
3.2.1  Search Results
The environmental scan found fifteen guidance 
documents on the organization of cancer diagnostic 
services. Although it was not the specific stated pur-
pose of many of the documents, some organizational 
elements of daps were addressed in each of the guid-
ance documents—for example, mandate, centralized 
access, scope of diagnostic activity, team criteria, 
linkages and collaborations, volume prerequisites, 
and quality indicators. In most cases, the conclusions 
derived from the guidance documents were supported 
by consensus-level evidence.
3.2.2  Outcomes
A consistent message was that coordinated and or-
ganized diagnostic assessment services managed by 
multidisciplinary teams with operational links to other 
specialty services resulted in reduced wait times and 
improved services—and possibly in improved patient 
outcomes. The guidance documents also outlined many 
of the requirements for a dap, including centralized 
access to diagnostic assessment services, multidisci-
plinary team criteria, and the diagnostic services needed 
to successfully operate a dap. Centralized access was 
most commonly characterized as a one-stop clinic, 
with integrated and coordinated cancer services, that 
provides seamless diagnostic assessment services.
The composition of the disease-specific multi-
disciplinary team included not only the appropriate 
spectrum of disease-specific professionals needed to 
perform a diagnostic assessment, along with the ap-
propriate disease-specific support personnel, but also 
coordinators and directors or chairs who were recom-
mended to ensure the coordination of services.
The common clinical examination, imaging, diag-
nostic, and staging procedures and surgical consultation 
procedures were listed in the guidance documents. Also 
reported were the pathology services, disease-specific 
tests, and supportive services that might be needed as 
part of the spectrum of diagnostic care. There was a 
general indication in the documents that the appropriate 
diagnostic investigations and procedures would lead to 
improved services and patient outcomes.
Several of the guidance documents reported the 
need for linkages to maintain communication between 
primary health care providers and the coordinated 
diagnostic and treatment services as patients navigate 
the system. It was suggested that, in low-volume or 
underserviced areas, smaller programs should have 
formal collaborative links with larger programs.
There was little evidence to indicate the patient 
volumes required to maintain one-stop daps. Each 
jurisdiction would need to determine the appropri-
ate volume requirements for each type or model of 
dap implemented.
Several documents established indicators of 
quality, with wait times being the most common 
indicator reported. Other documents recommended 
that the time from signs or symptoms suggestive 
of cancer to diagnosis should not exceed 4 weeks. 
A more thorough analysis of benchmarking is war-
ranted. The development of quality assurance through 
performance measurement and audit programs was 
also recommended.
4.  CONSENSUS PROCESS AND EXTERNAL 
REVIEW
The Diagnostic Assessment Standards Panel used 
the evidence that was available from the published 
literature, the environmental scan, and their expert 
opinion to reach consensus for standards on the 
organization and delivery of diagnostic assessment 
services in Ontario. The process of developing 
standards included the formation of the Diagnostic 
Assessment Standards Panel with a subset working 
group responsible for writing the draft standards. The 
panel met often through teleconferences and once in 
person to draft and approve the standards for practice 
before the standards were sent for external review. 
Approval was obtained through informal consensus 
at the meetings and also through an e-mail survey 
with 10 questions asking about the level of agreement 
with the completeness of the evidentiary base and the 
recommendations as stated. Conflicting views were 
noted and discussed, and it was agreed that the major-
ity opinion of the panel would be adopted.
Upon final approval of the draft by the Diag-
nostic Assessment Standards Panel, the document 
underwent internal review by the Report Approval 
Panel and the Scientific Manager of the pebc. The 
draft standards were then distributed for review to 
74 external Ontario stakeholders: 24 primary care 
providers, 17 chairs of provincial disease site groups, 
25 regional vice presidents of cancer programs and 
senior administrators, and 8 cancer screening program 
experts. External review included the opportunity for 
written feedback and a survey on level of agreement 
with the manner of evidence collection, with the 
process used to derive recommendations, and with 
the recommendations themselves. Responses were 
received from 11, 3, 12, and 5 participants in each 
of the respective groups (41% overall return rate). 
The written feedback from both the clinical and the 
administrative experts was similar in nature.
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Feedback was extremely positive. Most stake-
holders agreed (with higher mean values, maximum 
5, indicating stronger agreement) that there was a 
need for dap standards (mean: 4.6), that the standards 
were clear (mean: 4.1), that the draft standards as 
stated were acceptable (mean: 4.2), that the stan-
dards should be formally approved (mean: 4.3), and 
importantly, that the standards reflect an effective 
approach that will lead to quality improvements in 
the cancer system (mean: 4.5). There was also some 
indication that the standards would be challenging to 
implement (mean: 3.9), but that the draft standards 
for the organization of care were achievable (mean: 
4.0) and would reflect a more desirable system than 
current practice for improving the quality of patient 
care (mean: 4.3).
No major modifications to the draft standards 
were deemed necessary after external review; how-
ever, several minor modifications that had been sug-
gested were discussed and incorporated into the draft. 
Upon final review, the standards were presented to 
the Executive Team and the Board of Cancer Care 
Ontario, and the final version of the standards was 
formally approved by the Diagnostic Assessment 
Standards Panel. The final approved standards are 
set out in Appendix A.
5.  CONCLUSIONS
It is clear that organized, centralized systems with 
multidisciplinary team membership are considered 
the optimal organization for the delivery of diagnostic 
cancer assessment services. Even though much of the 
available literature is limited in quality, and expert con-
sensus opinion was often used to inform the guidance 
documents, the evidence across studies, the statements 
of credible guidance organizations, and the expert con-
sensus opinion of the Diagnostic Assessment Standards 
Panel all deliver a consistent message.
There are, however, significant and frequently cited 
challenges associated with the implementation of dap 
programs. There is a general consensus that implemen-
tation of the standards would not be cost-neutral and 
that additional resources (that is, human resources, new 
equipment, equipment replacement, and appropriate 
fees and incentives) would likely be necessary. The 
reallocation of scarce resources would likely cause 
hardship on other components of the cancer system, 
not only in terms of cost, but also in terms of demand 
for services beyond diagnostic assessment—that is, 
moving patients at a faster rate into treatment, with the 
associated potential for backlogging at that juncture. 
The transition protocol between diagnostic assessment 
and treatment management with multidisciplinary 
team membership would need to be carefully mapped 
out according to service and jurisdictional demands. 
The reorganization of care would also require strong 
and collaborative leadership between clinicians, clini-
cal administrators, hospital ceos, it leaders, and the 
local health integration networks across a variety of 
settings. The confluence between cancer and non-
cancer diagnostic care agendas was also seen as a 
barrier to implementation. The ability to affect change 
is limited in a system defined by multiple stakeholders 
representing many types of diseases, with cancer be-
ing only one; the competition with other non-cancer 
programs could create access barriers to clinicians and 
equipment. In addition, there may be challenges with 
the communication required to facilitate buy-in by all 
providers. There is also concern regarding the need 
for adequate it systems and connectivity, particularly 
in regions with a large rural demographic, where the 
“virtual program” model and single central registry are 
particularly relevant.
These are daunting challenges. However, success 
models emerging in Ontario show that the implemen-
tation of a dap can be achieved without undue burden 
to the health system. In Ottawa, a collaborative model 
of surgical cancer care was developed with the pri-
mary tertiary centre anchoring a virtual model with 
eight partnering hospitals in the region. An integral 
part of this model was the development of diagnostic 
assessment units (for patients with thoracic cancer, 
colorectal cancer, breast cancer, and prostate cancer) 
that have been opened under the umbrella of a central 
cancer assessment clinic. The cancer assessment clinic 
was developed to act as a central access point offering 
coordinated and streamlined multidisciplinary care, 
where a patient with a suspicion of cancer enters a 
system (organized by the four disease sites) that acts 
as the gateway and triage centre for access to coordi-
nated cancer services. Under this system, important 
collaborative linkages, known as “communities of 
practice,” have been established across the region, 
and improvements in patient and system outcomes, 
such as reductions in wait times, have been observed 
(Fung-Kee-Fung M. The Ottawa Hospital. Personal 
communication).
It is hoped that the organizational standards will 
be a useful tool in the development of diagnostic 
assessment models across various jurisdictions. It 
is also hoped that, regardless of the model chosen, 
coordinated rapid access to care in a multidisciplinary 
team environment will result in a “raising of the bar” 
in the provision of timely diagnostic assessment ser-
vices to patients.
The standards concerning daps were generated 
to meet the demand of cancer diagnostic assessment 
services in Ontario, but the structure and organization 
of a dap will be influenced by the regional and geo-
graphic realities of each jurisdiction, the diagnostic 
tests necessary to assess an organ system (symptom 
complexity or physical abnormalities, for instance), 
and the anticipated volume of cases. Hence, it is rea-
sonable to suggest that the standards will also be gen-
eralizable to other jurisdictions outside of Ontario.
Regardless of the dap structure implemented in 
any given jurisdiction, there will be an ongoing need 
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for a comprehensive and formal evaluation strategy 
not only to refine existing and future diagnostic as-
sessment services in Ontario, but also to help develop 
a more complete evidence base concerning the value 
of organized daps across many jurisdictions.
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appendix a  ONTARIO STANDARDS FOR 
DIAGNOSTIC ASSESSMENT PROGRAMS
The following standards for practice were informed 
by modest evidence from thirty-four published stud-
ies and fifteen unpublished guidance documents, but 
were primarily derived through the expert consensus 
opinion of the Diagnostic Assessment Programs 
Standards Panel. The standards were reviewed ex-
ternally by Ontario stakeholders, including primary 
care providers, chairs of Ontario provincial disease 
site groups, regional vice presidents of cancer pro-
grams, senior administrators, and cancer screening 
program experts.
SCOPE
Improving access to better and more rapid cancer 
diagnosis has been identified as a priority for Cancer 
Care Ontario (cco) and the Government of Ontario. A 
first step in realizing this objective is the development 
of provincial standards that define the organizational 
and practice-setting features expected of a diagnostic 
assessment program (dap). These standards represent 
one of a series of strategies that are needed to achieve 
the overall goal of improved rapid access to diagnosis. 
The standards that follow, which were developed by 
the Diagnostic Assessment Standards Panel, apply to 
the organization of daps and include the full spectrum 
of multidisciplinary diagnostic assessment leading to 
treatment. These standards will be routinely updated 
as the evidentiary support for the recommendations, 
particularly the evidence related to evaluation and 
outcomes data, matures.
PURPOSE AND PRINCIPLES
The mandate of a dap is to coordinate patient care 
from referral to definitive diagnosis. These are the 
guiding principles for the dap:
●    To ensure that an environment of patient-centred 
care is established
  ●    Patients have equal access to high-quality 
diagnostic care regardless of where they live 
in the province.
  ●    Patients are supported throughout the diag-
nostic process.
  ●    Patients have a diagnosis of cancer made or 
ruled out in a timely fashion.
●    To ensure that a coordinated referral and follow-
up system is established
●    To ensure that indicators of quality are established 
and monitored to evaluate performance outcomes
●    The objectives of the dap will be enabled by the 
development and implementation of common 
evidence-based regional or provincial guidelines 
(or both), which may include:
  ●    Disease-specific protocols regarding diagnos-
tic work-ups
  ●    Service frameworks for primary care providers
  ●    Wait-time benchmarks
The dap must be able to demonstrate compliance 
(alignment) with these principles.
DIAGNOSTIC ASSESSMENT PROGRAMS
The structure and organization of a dap will be influ-
enced by the regional and geographic realities of each 
jurisdiction, the diagnostic tests necessary to assess 
an organ system (dealing with symptom complexity 
or physical abnormalities), and the anticipated vol-
ume of cases. Two core organizational models are 
recommended:
●    One-Stop Diagnostic Assessment Services
    One-stop single-location assessment services 
are those that provide the totality of diagnostic 
services in one place and, where clinically ap-
propriate, within one patient visit.
  ●    One-stop assessment services may also pro-
vide total service across the cancer continuum 
(that is, from screening to diagnosis to treat-
ment and follow-up).
  ●    The size of the region and the scope of care 
provided (that is, diagnostic versus total care) 
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will determine whether a region will have one 
or more programs.
  ●    For rare cancers or where diagnostic and 
treatment centres of excellence already exist, 
diagnostic assessment services in one region 
may also provide services to patients from 
several regions.
  ●    The organization of assessment services will 
typically be disease-site specific, but in some 
cases, an assessment program may oversee 
multiple tumour types.
●    Virtual Diagnostic Assessment Services
    Where patient populations and geographic dis-
persion do not permit single-location assessment 
services, virtual programs should be explored
  ●    within a region or city.
      These virtual systems of diagnostic services 
are spread out geographically across the re-
gion or city, but coordinated centrally.
  ●    across regions.
      In these virtual systems (“collaborative sys-
tems”), the distribution of diagnostic services 
crosses regional barriers. For example, for 
rare cancers, diagnostic expertise may be 
found in only a few locations in the province. 
Similarly, some procedures may require the 
use of equipment or technologies readily 
available in one region but not in another.
Individual regional cancer programs, in collabora-
tion with the local health integration networks, will 
be responsible for determining the most appropriate 
organization of the assessment systems. No currently 
available evidence indicates the population-based 
volumes required to support any particular model, 
but it is important to recognize that high-quality di-
agnostic care is not defined by having a dap for every 
disease site in every region. Indeed, for rare cancers 
(for example, head-and-neck cancers or sarcoma), 
efforts to enhance the current provincial systems of 
diagnostic and treatment services in a few centres is 
a more desirable quality goal than is the provision of 
such services in multiple regions. In contrast, regions 
should have local mechanisms to deal with the rapid 
diagnosis of high-volume cancers (for example, lung, 
breast, colorectal, prostate).
When developing a business case for a specific 
dap model, the following elements should be consid-
ered to justify the choice of model:
●    How current diagnostic systems (that is, including 
the organization of staff, equipment, processes, 
and so on) within a region can be restructured and 
redesigned to improve access and quality.
●    Volume–outcome literature for specific diagnostic 
procedures.
●    Cost-effectiveness and clinical efficiencies of 
competing models.
●    Population-based estimates of disease incidence 
and prevalence for each tumour type.
Regardless of the model chosen, meeting com-
mon standards for centralized access, scope of activ-
ity, team criteria, linkages and collaborations, and 
performance indicators is required.
●    Regional Centralized Access to daps
    A simple and efficient access strategy is a key 
mechanism for improving the health care experi-
ence of the patient and the quality of diagnostic 
care. Therefore, regardless of the model chosen, 
a coordinated, centralized, single-point-of-entry, 
central access system (cas), is an essential ele-
ment of the dap.
Variation in entry systems may be expected 
across regions: for example, low and mid-size 
populations are more likely to be able to sup-
port a single-entry cas; a large population region 
may require a different approach. High-quality 
diagnostic care can be achieved only by having 
coordinated points of entry, particularly for the 
diagnostic work-up of suspected similar cancers, 
and by implementing systematic referral protocols 
that supersede existing patterns of referral where 
quality and access improvements can be made. A 
cas should be designed explicitly to reduce varia-
tions in demand or wait times across the region.
The cas will be responsible for ensuring that 
eligible patients are brought into a dap and that 
the diagnostic plans for patients are developed 
and communicated to the patients, referring phy-
sicians, other primary care providers, and local 
multidisciplinary care conference (mcc) coordina-
tors, using regional and provincial templates. The 
patient version of the diagnostic plan will include 
the appointment schedule of all procedures, de-
scriptions of each procedure, and the preparatory 
activities (if appropriate) for each procedure. The 
cas will be responsible for communicating the 
patient version of this plan to the patient by the 
most appropriate method (telephone, mail, e-mail, 
Internet). The clinician version will include the 
appointment schedule of all procedures booked 
for the patient, and the mcc version will include 
information about the patient and the appointment 
schedule of all procedures.
●    Entry Points to the cas
    Access to the cas will typically be from a variety 
of entry points, such as
  ●    primary care providers or specialists.
      Patients who meet specific cas referral cri-
teria (see “Guidelines and Standards”) will 
be referred.
  ●    screening programs.
      Screening programs such as the Ontario 
Breast Screening Program, the provincial 
Colorectal Screening Program, and the On-
tario Cervical Screening Program will refer 
to the cas patients who meet specific criteria 
according to appropriate protocols.
  ●    self-referral.
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      Given the significant proportion of the 
public who have no access to primary care 
providers, a system for patient self-referral 
may be necessary.
Appropriate pre-screening, following cas 
protocols, by a qualified clinical coordinator will 
be required if self-referral is part of the dap.
      In these instances, the dap should ensure that 
appropriate primary care services are avail-
able to support ongoing care, which may 
include the development of formal linkages 
between the dap and primary care networks or 
family practice teams. Where that is not pos-
sible, the dap may need to ensure that these 
services are provided within the dap itself.
      The ability of these groups to enter into the 
dap cas must be demonstrated.
●    Operational Features of the cas
    Several operational features are essential elements 
of a cas:
  ●    Entry to the cas
      Each dap will determine the most appropriate 
modality of entry to its cas (telephone, Inter-
net, fax). However, common across all entry 
strategies for all prospective patients will be 
the application of referral and triage criteria 
requirements at the intake point.
  ●    Fast-access booking
      Protected booking slots must be accessible 
to the dap for specific diagnostic procedures 
and clinic appointments with specialists. 
This approach will distribute patient cases 
more evenly, facilitate patient flow, and 
reduce wait times.
  ●    Priority-booking system
      Triage should be performed by the cas be-
fore the first visit to the dap, and an urgent 
referral mechanism must be implemented 
for all daps.
  ●    Open-access booking
      Access to booking for specific diagnostic 
procedures must be open to all clinicians who 
adhere to predefined referral criteria and diag-
nostic assessment protocols (see “Standards 
and Guidelines”)
SCOPE OF CANCER DIAGNOSTIC ACTIVITY 
WITHIN A DAP
Each dap will provide the spectrum of clinical diag-
nostic and supportive care services for the tumour 
type or types that fall under the mandate of the 
program. Appropriate equipment, technologies, and 
expertise will be required to meet the scope of the 
diagnostic activities for each assessment unit. Where 
necessary diagnostic or supportive services are not 
available, linkages to those necessary services will 
need to be established to eliminate any gaps in care. 
The spectrum of diagnostic work-up must be tailored 
to the specific tumour type, but may include any or 
all of these services:
●    physical examination,
●    imaging tests (radiography, computed tomog-
raphy, magnetic resonance imaging, positron-
emission tomography, ultrasonography),
●    diagnostic procedures (for example, ultrasound-
guided needle biopsy),
●    surgical consultation,
●    tumour-specific surgical procedures,
●    pathology analyses, and
●    reporting.
In addition, supportive care services that may be 
needed include education, psychosocial support, dietetics, 
genetic counselling, or other types of supportive care.
CANCER DIAGNOSTIC ASSESSMENT TEAM 
CRITERIA
It is recommended that assessment services within each 
dap be composed of a dedicated multidisciplinary team, 
with each member having explicit roles, responsibili-
ties, and accountabilities. Specialists (for example, gas-
troenterologists, respirologists) and surgeons will take 
the clinical lead in the diagnostic processes, with the 
assessment coordinators serving as primary commu-
nication leads. There will be common team elements 
across the assessment programs, and disease-specific 
specialists will be required for each dap.
CANCER DAPS LINKAGES AND 
COLLABORATIONS
Linkages, collaborations, and communication strate-
gies will vary across the daps. To facilitate patient ac-
cess, each dap should have formalized bi-directional 
linkages with primary care providers, other related 
family health teams or services (including psychoso-
cial support), and any related networks and organiza-
tions. Each region will have to develop its own system 
to fit the specific needs of the region and the various 
tumour types. There will, however, be some core 
elements that should be common across all models 
of diagnostic assessment services.
Assessment Coordinator
With the assessment coordinator acting as the main 
source for information exchange, the assessment pro-
grams will establish formal linkages, collaborations, 
or communication strategies with key stakeholders, 
including patients entering the cancer diagnostic as-
sessment system, cancer screening programs (where 
applicable), primary care providers (including family 
and general practitioners and primary care nurse prac-
titioners), other referral systems, multidisciplinary 
case conference teams, and related specialists and 
supportive care services.
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Primary Care Provider
Formal linkages with primary care providers are es-
sential to a successful dap. Primary care providers 
must be supported with appropriate tools and products 
(for example, services plans, guidelines) that provide 
evidence-based recommendations about appropriate 
criteria for referral of patients to the dap and commit-
ted bi-directional communication with the assessment 
team, beginning at point of entry, through the patient’s 
work-up until cancer is diagnosed or ruled out, and to 
the development and implementation of the treatment 
plan with a definitive diagnosis.
MCC Team/Treatment Team
A clearly identified transition protocol for the patient 
from the dap to the mcc team or treatment team must 
be established. The protocol must articulate provider 
accountabilities and the communication strategy for 
patients and providers.
CROSS-DAP COLLABORATION
Formal collaborative linkages among the daps are en-
couraged. The formal documentation of accountabili-
ties among the various entities or individuals and the 
dap will be needed, as will communication strategies or 
protocols with clear reporting formats, to ensure com-
mon data collection and reporting, especially regard-
ing outcomes reporting. With standardized reporting 
systems and clear expectations concerning reporting, 
the focus should be on accountability and on the col-
lection and delivery of data to enable the assessment 
of quality indicators and other benchmarks.
Each dap will be responsible for developing a 
unique diagnostic assessment system, but several 
models that currently exist within Ontario could help 
to guide that development. For example, in Ottawa, the 
Ontario Breast Screening Program has documented the 
development of a Breast Assessment Program that out-
lines many key features on which to base a coordinated 
breast cancer diagnostic assessment service.
INDICATORS OF QUALITY FOR CANCER DAPS
It is recommended that a range of process and clini-
cal indicators of quality be developed, measured, and 
monitored to evaluate the performance of each dap. 
These indicators should reflect the specific needs of 
each region or tumour type, but they should also be 
standardized to match provincial benchmarks devel-
oped by cco or the Government of Ontario. At both 
levels, fundamental indicators relevant to the daps 
should be identified to drive the quality agenda at key 
points. These must include
●    time intervals.
  ●    The time from abnormal screen or primary 
care referral to entry into the dap.
  ●    The time from entry into the dap to cancer 
diagnosis or rule-out.
●    clinical outcomes.
  ●    Upstaging
  ●    Mortality
●    quality of care.
    The percentage of patients receiving the appro-
priate diagnostic work-up according to evidence-
based guidelines, service plans, and protocols
●    patient satisfaction.
    Patient satisfaction throughout the cancer diag-
nostic assessment system (for example, expansion 
of the Ambulatory Oncology Patient Satisfaction 
Survey) Other indicators may include, but are not 
limited to,
  ●    program efficiency indicators (avoidance 
of duplication);
  ●    completeness of cancer-stage reporting 
at diagnosis;
  ●    percentage of pathology reports meeting pro-
vincial information completeness standards;
  ●    clinician team functioning and satisfaction;
  ●    reporting of cancer services integration 
through the assessment of linkages, collab-
orations, and communication both within and 
external to the dap; and
  ●    impact on regional performance.
GUIDELINES, STANDARDS, AND SERVICE 
FRAMEWORKS
To successfully implement a quality agenda dedicated 
to reducing wait times for diagnostic services and 
to improve the quality of those services, there is a 
requirement for recommendations, benchmarks, and 
targets, including
●    guidelines and service frameworks for primary 
care providers.
    Facilitation by cco is recommended for the devel-
opment of provincial evidence-based guidelines 
and service frameworks for primary care pro-
viders. A comprehensive knowledge exchange 
strategy should be developed and promoted for 
the uptake of the guidelines.
●    evidence-based investigative algorithms and 
guidance documents.
    Facilitation by cco is recommended for the devel-
opment of provincial evidence-based algorithms 
that articulate the most effective diagnostic 
procedures and the appropriate pathways for the 
work-up for patients suspected to have cancer. 
These guideline documents should be developed 
for all major cancer diagnoses and should serve 
as the foundation for the local and regional diag-
nostic pathway protocols and algorithms required 
to support the daps.
●    wait-times benchmarks.
    Facilitation by cco is recommended for the de-
velopment of provincial benchmark targets for 
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various significant intervals within the diagnostic 
work-up.
CONCLUSIONS
An essential need is that implementation of the daps 
be accompanied by a comprehensive evaluation 
framework. The standards will evolve and be refined 
over time as a consequence of the new information 
gained through the learning experience of imple-
menting the daps. Future iterations will focus on 
the requirements for comprehensive pathway and 
risk assessment models for all cancer types in the 
ongoing effort to improve patient outcomes.
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